Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization: AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech (AIM) specializes in developing treatments for viral pathologies. The growth potential is immense, as a single successful development could offset all costs and generate colossal profits. However, prolonged disputes with the FDA and internal shareholder conflicts are creating significant pressure. The market's valuation dynamics at 0.00 currently price in the company's total dependence on external contractors for drug production.
AIM (AIM ImmunoTech, Inc.): analytical breakdowns and indicator data
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book value of equity indicators:
- debt level and financial liquidity data:
Total Debt to Capital AIM ImmunoTech|AIM - Long-Term Liabilities to Capital|Short-Term Debt to Capital AIM ImmunoTech|AIM - Company Aggregate Debts|Debts to Book Capitalization AIM ImmunoTech Inc.|AIM - Long-Term Debt Volume|Company Short-Term Debt AIM ImmunoTech|Quick Liquidity Indicator aimimmuno.com
- net income and valuation multiples indicators:
AIM - Final Profit|Projected Future Earnings AIM ImmunoTech|AIM - Business Payback Period|Future Price to Earnings AIM ImmunoTech Inc.|AIM - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AIM ImmunoTech Inc.|AIM - Operating profit before deduction of amortization|Net earnings per share for the last 12 months AIM ImmunoTech|AIM - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months aimimmuno.com|AIM - Earnings per share growth this year|Net earnings per share growth forecast for next year AIM ImmunoTech
Fundamental company analysis:AIM ImmunoTech Inc. AIM
To objectively measure the operational efficiency of AIM ImmunoTech, investors must compare the market value of assets and liabilities against actual earnings before depreciation and amortization. The EV/EBITDA multiple trend on the GURU.Markets platform reflects the business price excluding accounting assumptions, allowing for an assessment of any overpayment for the asset. For this biopharmaceutical innovator, this indicator is critical as it links the development costs of immune drugs with market capitalization.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Argenx ARGX|BNTX - Enterprise Value to EBITDA Ratio|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|PTGX (Protagonist) - Enterprise Value to EBITDA Ratio|Immunovant Inc (IMVT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kiniksa Pharmaceuticals Ltd|Enterprise Value to Operating Income Before Depreciation GRFS (Grifols Biemat)|EV/EBITDA Multiple ADPT|CLDX - Company Value to EBITDA|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|EV/EBITDA Multiple BioCryst Pharmaceuticals, Inc. BCRX|Vera Pharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Dianthus Corp DNTH|Pharvaris N.V. (PHVS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio AbCellera|Enterprise Value to EBITDA Ratio TRML|PGEN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PHAR|Total Company Value to Operating Income Before Depreciation Ratio Nektar Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|ZBIO - Enterprise Value to EBITDA Ratio|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Bio Inc (GOSS) - Enterprise Value to EBITDA Ratio|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|Septerna Pharma (SEPN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals|Enterprise Value to Operating Income Before Depreciation SVRA (savarapharma.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|ANAB - Company Value to EBITDA|Astria Pharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ENGN (enGene Corp)|RAPT Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA Aerovate Therapeutics Inc|ACRS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Kyverna Therapeutics Inc.|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|CABA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple VTYX|EV/EBITDA Multiple theratech.com (THTX)|EV/EBITDA Multiple AVTX (Avalo Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Eledon Pharmaceuticals Inc. (ELDN)|AGEN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Climb Bio, Inc (CLYM) - Enterprise Value to EBITDA Ratio|Zura Bio (ZURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ATYR (atyrpharma.com)|ADAG (Adagene Inc) - EV/EBITDA Multiple|IMA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple STTK|EV/EBITDA Multiple equilliumbio.com (EQ)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Connect Biopharma Holdings Limited CNTB|Business Value to Operating Income Before Depreciation IMUX|ATRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|InflaRx N.V. (IFRX) - Enterprise Value to EBITDA Ratio|XFOR: EV/EBITDA Multiple|Adicet Bio, Inc. (ACET) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CELU|INMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BRNS|Total Company Value to Operating Income Before Depreciation Ratio Kezar Life Sciences Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SAB Biotherapeutics, Inc SABS|AKTX - Enterprise Value to EBITDA Ratio|ENLV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Q32 Bio Inc. (QTTB) - Enterprise Value to EBITDA Ratio|GOVX (GeoVax) - Enterprise Value to EBITDA Ratio|Edesa Biotech Inc (EDSA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iBio Corp|Enterprise Value to Operating Income Before Depreciation CARM (Carisma Tx)|EV/EBITDA Multiple XTLB|BOLT - Company Value to EBITDA|EV/EBITDA Multiple HCWB (HCW Biologics)|EV/EBITDA Multiple Aptevo Therapeutics, Inc. APVO|Aditxt Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRI Bio Corporation GRI|XORTX Therapeutics Inc. (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio reshapelifesciences.com|Enterprise Value to EBITDA Ratio REVB|INDP: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SCNI|Total Company Value to Operating Income Before Depreciation Ratio calcimedica.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
